Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Phase II Trial to Evaluate Safety, and Pharmacodynamics of Repeated Subcutaneously Administered RBD1119 in Participants With CAD

NCT07884136 is registered in ClinicalTrials.gov with Ribocure Pharmaceuticals AB as lead sponsor.

NCT NCT07884136
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07884136 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Phase II Trial to Evaluate Safety, and Pharmacodynamics of Repeated Subcutaneously Administered RBD1119 in Participants With CAD
Lead sponsor
Ribocure Pharmaceuticals AB
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 16, 2026
Completion date
March 18, 2028
Enrollment
200 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

stable coronary artery disease